혈액뇌장벽 통과 약물전달 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측, 기술별, 용도별, 지역별, 경쟁별(2020-2030년)

Global Drug Delivery Across Blood Brain Barrier Market was valued at USD 1.93 Billion in 2024 and is expected to reach USD 2.66 Billion by 2030 with a CAGR of 5.46% during the forecast period. The global Drug Delivery Across Blood Brain Barrier Market is driven by the increasing prevalence of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and brain tumors, which require effective treatments targeting the brain. The blood-brain barrier's selective permeability often limits the delivery of therapeutic agents to the central nervous system (CNS), creating a significant challenge for treatment. Advances in nanotechnology, targeted drug delivery systems, and biologics are helping to overcome these challenges, enabling more efficient and precise delivery of drugs across the blood-brain barrier. The growing focus on developing innovative therapies for CNS disorders, alongside the rise in research and development funding, is accelerating market growth. The demand for personalized and minimally invasive treatments is further driving the adoption of novel drug delivery technologies.

Key Market Drivers

Increasing Prevalence of Neurological Disorders

The rising global prevalence of neurological disorders is one of the primary factors driving the Global Drug Delivery Across Blood Brain Barrier Market. Neurological disorders, such as Alzheimer's disease, Parkinson's disease, brain tumors, and multiple sclerosis, are becoming more common due to factors such as aging populations, lifestyle changes, and genetic predispositions. These disorders are often difficult to treat because they involve the brain, which is protected by the blood-brain barrier (BBB)-a selective membrane that restricts the entry of most drugs. In 2021, neurological conditions accounted for 443 million years of healthy life lost due to illness, disability, and premature death (disability-adjusted life years), making them the leading contributor to the global disease burden, surpassing cardiovascular diseases.

As a result, therapies for conditions like Alzheimer's, where drug delivery to the brain is critical, often face significant limitations. The increasing number of patients suffering from these conditions is creating a growing need for advanced drug delivery technologies capable of overcoming the BBB. As the burden of these neurological diseases continues to grow, the demand for effective therapies that can reach the brain is intensifying, thereby boosting the market for drug delivery systems designed to cross the blood-brain barrier.

Technological Advancements in Nanotechnology

Technological innovations in nanotechnology have significantly contributed to the growth of the Global Drug Delivery Across Blood Brain Barrier Market. Nanotechnology has allowed researchers to develop nanoscale carriers, such as liposomes, dendrimers, and nanoparticles, that can encapsulate drugs and deliver them directly to the brain. These nanocarriers can be engineered to cross the BBB more effectively by exploiting the properties of the blood-brain barrier, such as endocytosis and transcytosis. Nanoparticles are small enough to bypass the barrier, while the surface properties of these particles can be modified to enhance drug delivery, targeting specific areas of the brain. These systems can improve the bioavailability of drugs, reduce side effects, and enhance drug stability. Nanotechnology also enables the design of sustained release formulations, which can provide long-term therapeutic benefits. As researchers continue to innovate and refine these technologies, nanotechnology remains a crucial driver of the global market, offering promising solutions to overcome the challenges of drug delivery to the brain.

Growing Demand for Targeted and Personalized Therapies

The growing emphasis on personalized medicine and targeted therapies is another significant factor driving the Global Drug Delivery Across Blood Brain Barrier Market. Traditional treatments for neurological disorders often involve a "one-size-fits-all" approach, which may not be effective for every patient. Personalized therapies, however, focus on tailoring treatments to an individual's specific condition, genetic profile, and molecular characteristics. These therapies can be more effective in targeting the brain cells responsible for the disease while minimizing side effects. For drug delivery across the blood-brain barrier, targeted drug delivery systems that can specifically reach the site of action within the brain are becoming increasingly important. The need for personalized treatments has pushed the development of novel delivery technologies that allow for precise targeting of brain regions and cell types, improving treatment outcomes. This demand for personalized therapies is accelerating the development of drug delivery systems that can effectively penetrate the blood-brain barrier and deliver drugs to the brain with enhanced specificity and reduced systemic toxicity.

Rising Incidence of Brain Cancer

The increasing incidence of brain cancer, including glioblastoma and brain metastases, is contributing to the growing demand for drug delivery systems that can overcome the blood-brain barrier. Brain cancer treatments traditionally rely on chemotherapy, but the effectiveness of such therapies is limited due to the blood-brain barrier's ability to prevent many drugs from reaching the tumor site. This challenge has spurred the development of specialized drug delivery systems, such as convection-enhanced delivery, that can bypass the BBB and deliver high concentrations of drugs directly to the tumor. According to

Cancer Council Victoria, In 2022, 1,359 Victorians were diagnosed with brain and CNS cancer, including 641 males and 718 females, accounting for 61% and 39% of total diagnoses, respectively. Additionally, 859 Victorians were diagnosed with benign brain and CNS tumors in 2022, with 336 males and 523 females, representing 39.1% and 60.9% of all non-malignant brain and CNS cancer diagnoses in the state. Benign brain and CNS tumors are currently diagnosed at a rate of 7.6 per 100,000 males and 10.6 per 100,000 females. The median age at diagnosis for benign brain and CNS tumors is 58 years for males and 59 years for females.

The combination of chemotherapy with biologics or immunotherapies is gaining attention, as it may offer a more effective treatment strategy. The rising number of brain cancer cases globally is expected to continue to fuel demand for innovative drug delivery technologies capable of targeting the brain and enhancing the therapeutic effect of cancer treatments.

Increased Awareness and Diagnosis of Neurological Disorders

There has been a noticeable increase in the awareness and diagnosis of neurological disorders in recent years. A major new study published in The Lancet Neurology reveals that, in 2021, over 3 billion people globally were living with a neurological condition.

Early detection of conditions like Alzheimer's disease, Parkinson's disease, and other neurodegenerative diseases has led to a rise in the number of patients seeking treatment. The growing recognition of the importance of brain health, coupled with advances in neuroimaging and diagnostic techniques, is facilitating earlier intervention and more tailored treatments for patients. With earlier diagnosis, healthcare providers are seeking novel drug delivery methods that can prevent disease progression and provide better patient outcomes. This increased awareness and diagnosis are driving the demand for specialized drug delivery systems that can effectively target the brain and manage neurological diseases.

Key Market Challenges

Blood-Brain Barrier's Selectivity and Complexity

The blood-brain barrier (BBB) remains one of the most significant obstacles to drug delivery to the brain. The BBB is a complex and highly selective membrane that serves as a protective barrier, preventing many therapeutic agents from entering the brain. Its selective permeability makes it difficult for drugs, especially larger molecules like biologics, to cross into the central nervous system. While various techniques, such as nanoparticles and receptor-mediated transport, have been developed to bypass the BBB, overcoming its strict barrier remains a major challenge. Ensuring drugs can pass through the BBB without damaging its integrity or causing adverse effects is a key issue that researchers and pharmaceutical companies continue to face in the development of brain-targeted therapies.

Limited Effectiveness of Current Drug Delivery Methods

Although various drug delivery methods have been developed to cross the BBB, many still face limitations in terms of effectiveness, stability, and precision. Techniques like nanoparticles, liposomes, and convection-enhanced delivery show promise but often struggle with issues such as low drug payload, short circulation time, and the difficulty of achieving controlled release. These methods may not target the specific regions of the brain where treatment is needed most, leading to suboptimal therapeutic outcomes. The effectiveness of these delivery systems is often limited by their ability to deliver sufficient concentrations of the drug to the target site while minimizing systemic toxicity. Achieving both precision and efficacy remains a significant challenge in the market.

High Development and Production Costs

Developing and manufacturing drug delivery systems capable of overcoming the blood-brain barrier is a complex, time-consuming, and costly process. From designing the drug formulation to conducting preclinical and clinical trials, the costs associated with research and development (R&D) for these technologies can be very high. The production of these advanced drug delivery systems requires specialized equipment, technology, and facilities, further driving up costs. These high expenses can limit the affordability and accessibility of treatments, particularly for patients in low-income regions or emerging markets. The high cost of development may also hinder small and medium-sized enterprises from entering the market, creating a barrier for innovation.

Key Market Trends

Advancements in Drug Formulations and Biologics

The development of advanced drug formulations and biologics is helping to overcome the challenges posed by the blood-brain barrier. Biologics, such as monoclonal antibodies, gene therapies, and RNA-based treatments, are gaining traction in the treatment of neurological disorders due to their ability to target specific biological pathways. However, biologics often face difficulties in crossing the blood-brain barrier due to their large molecular size and structural complexity. To address this, new drug formulations and delivery systems are being developed that facilitate the transport of biologics across the BBB. These include conjugated antibodies, liposomal formulations, and nanoemulsions, which can encapsulate biologic drugs and protect them from degradation. These advancements in biologic drug formulations are opening new avenues for the treatment of previously untreatable neurological conditions and are becoming a key driver of growth in the market for drug delivery across the blood-brain barrier.

Increased Research and Development Investments

The growing investments in research and development (R&D) for drug delivery systems is another major driver of the Global Drug Delivery Across Blood Brain Barrier Market. As pharmaceutical companies and academic institutions focus more on the brain and neurological diseases, significant resources are being directed towards finding new ways to cross the blood-brain barrier effectively. In 2023, the EU's research and development expenditure relative to GDP reached 2.22%, slightly up from 2.21% the previous year. The EU spent €381 billion on R&D in 2023, an increase from 2.08% of GDP in 2013. Over the decade between 2013 and 2023, the majority of R&D spending occurred in the business enterprise sector, rising from 1.33% of GDP in 2013 to 1.47% in 2023, reflecting a 10.53% overall increase in this sector.

Researchers are exploring innovative approaches such as the use of biomolecules to open the blood-brain barrier temporarily or employing ultrasound and microbubbles to increase permeability and facilitate drug delivery. With the rise in government funding and private investments in R&D for neurological disorders, there is a growing momentum for the development of novel delivery systems. The increasing availability of technologies like gene editing and high-throughput screening is accelerating the discovery of new drug candidates that can target the brain more effectively. As a result, the drug delivery market is expanding rapidly, with promising solutions that could potentially transform the treatment landscape for brain-related diseases.

Segmental Insights

Technology Insights

Based on the Technology, the Trojan Horse Approach is currently one of the most dominant strategies in the Global Drug Delivery Across Blood Brain Barrier Market. This approach is based on the concept of using a carrier molecule, typically a peptide or an antibody, that can cross the blood-brain barrier and deliver the therapeutic drug to the brain. The Trojan Horse method essentially "hides" the drug within a transport molecule that is recognized and transported across the blood-brain barrier via receptor-mediated transcytosis. This method exploits the natural transport mechanisms of the BBB, where molecules that resemble essential nutrients or other naturally occurring substances are allowed to cross.

The Trojan Horse strategy has gained traction due to its effectiveness in overcoming the BBB's selective permeability. Unlike other approaches that rely on physical disruption or temporary opening of the BBB, this method is non-invasive and can deliver a wide range of therapeutic agents, including large molecules such as biologics, peptides, and nucleic acids. By utilizing a ligand that specifically targets receptors expressed on the surface of endothelial cells in the BBB, the Trojan Horse approach enables targeted drug delivery to specific regions of the brain. This ability to selectively target brain areas that are affected by neurological diseases, such as Alzheimer's, Parkinson's, and brain tumors, has made it a popular and effective strategy. One of the major advantages of the Trojan Horse approach is its ability to deliver biologic agents that would otherwise not be able to cross the BBB. These biologics include large molecules like monoclonal antibodies and gene therapies, which hold promise for treating complex neurological disorders but face the challenge of being unable to penetrate the BBB. By conjugating these biologics with molecules that can cross the BBB, such as transferrin or insulin, the Trojan Horse strategy makes it possible to bypass this barrier without the need for direct manipulation or opening of the BBB, thus reducing the risk of side effects and complications.

Application Insights

Based on the Application segment, Alzheimer's Disease dominated the Global Drug Delivery Across Blood Brain Barrier Market. Alzheimer's disease, a neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes, has become one of the most significant health challenges worldwide due to the aging global population. As the prevalence of Alzheimer's disease rises, particularly in aging populations, the demand for effective therapies capable of targeting the brain and addressing the underlying pathology of the disease is increasing. In 2024, approximately 6.9 million Americans aged 65 and older are living with Alzheimer's, with 73% of them being 75 or older. Around 1 in 9 people aged 65 and older (10.9%) have Alzheimer's. Nearly two-thirds of those affected by Alzheimer's in the U.S. are women.

Alzheimer's disease is closely linked to the accumulation of beta-amyloid plaques and tau tangles in the brain, both of which disrupt normal neuronal function. However, the blood-brain barrier (BBB) presents a major challenge in treating Alzheimer's, as it limits the ability of drugs, especially large biomolecules, to reach the affected areas of the brain. Consequently, drug delivery methods that can bypass or overcome the BBB are crucial for developing more effective treatments for Alzheimer's. The development of drug delivery systems, such as the Trojan Horse approach, receptor-mediated transcytosis, and nanotechnology-based solutions, has become a focal point of Alzheimer's research, as these systems hold the potential to deliver drugs directly to the brain regions involved in the disease.

While there is currently no cure for Alzheimer's disease, existing treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, only provide symptomatic relief rather than altering the disease's progression. This creates a substantial opportunity for novel drug delivery systems designed to target amyloid plaques, tau tangles, or other disease-related biomarkers. The focus on Alzheimer's disease has led to significant investments in research and development (R&D), with pharmaceutical companies and academic institutions exploring new ways to enhance drug delivery across the BBB. These developments are accelerating the adoption of advanced drug delivery techniques and fueling market growth. Alzheimer's disease has garnered significant attention in the pharmaceutical industry due to its societal and economic impact. The increasing burden on healthcare systems and the growing number of Alzheimer's patients worldwide are driving the demand for innovative solutions to effectively deliver therapeutics to the brain. This has led to collaborations between pharmaceutical companies, biotech firms, and research institutions, further promoting the development of novel drug delivery technologies that can target Alzheimer's-specific pathways. As Alzheimer's disease progresses, it causes significant damage to the brain, which makes early detection and intervention critical. This increases the importance of developing drug delivery systems that can effectively cross the BBB and deliver therapies before irreversible damage occurs.

Regional Insights

North America is currently dominating the Global Drug Delivery Across Blood Brain Barrier Market. This dominance is primarily due to the region's advanced healthcare infrastructure, high levels of research and development (R&D) investment, and the presence of major pharmaceutical companies and biotech firms focused on innovations in drug delivery technologies. The United States, in particular, plays a key role in driving the market forward, as it is home to some of the world's leading pharmaceutical and biotechnology companies that are heavily invested in overcoming the challenges associated with drug delivery to the brain.

One of the primary reasons for North America's dominance is the significant level of funding allocated to the research and development of new drug delivery methods for neurological diseases, such as Alzheimer's disease, Parkinson's disease, and brain cancer. Both public and private sectors in North America are investing heavily in R&D, enabling the development of new and improved drug delivery systems. Research institutions, universities, and healthcare organizations in the U.S. and Canada collaborate with pharmaceutical companies to explore innovative technologies, such as nanoparticles, nanocarriers, and the Trojan Horse approach, all aimed at improving the delivery of drugs across the blood-brain barrier.

In addition to R&D, North America's strong regulatory framework is another factor contributing to the region's leadership in the market. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and Health Canada are actively working to streamline approval processes for drug delivery technologies that can cross the blood-brain barrier. These regulatory bodies have provided guidelines and approval pathways that facilitate the development and commercialization of novel treatments targeting neurological conditions. North American regulators are often more open to innovative drug delivery technologies, which has encouraged companies to prioritize the development of such systems in the region.

The growing prevalence of neurological disorders in North America also fuels the demand for advanced drug delivery systems. With the aging population in the U.S. and Canada, the number of individuals affected by age-related neurological diseases like Alzheimer's and Parkinson's is steadily increasing. This creates a large patient base in need of more effective treatments, which, in turn, drives the demand for drug delivery systems capable of crossing the blood-brain barrier. The increasing awareness about brain health, coupled with the high level of healthcare spending, has pushed governments and private institutions to focus on finding innovative solutions for these challenges.

Key Market Players

• Ossianix Inc.
• Insightec Ltd.
• F. Hoffmann-La Roche Ltd
• JCR Pharmaceuticals Co., Ltd.
• Lauren Sciences LLC
• Bioasis Technologies Inc.
• Ceres Brain Therapeutics
• Nanomerics Ltd.
• NEUWAY Pharma GmbH
• Genervon Biopharmaceuticals LLC

Report Scope:

In this report, the Global Drug Delivery Across Blood Brain Barrier Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug Delivery Across Blood Brain Barrier Market, By Technology:

• Trojan Horse Approach
• Bispecific Antibody RMT Approach
• Increasing the Permeability of BBB
• Passive Diffusion
• Others

Drug Delivery Across Blood Brain Barrier Market, By Application:

• Alzheimer's Disease
• Epilepsy
• Parkinson's Disease
• Multiple Sclerosis
• Hunter's Syndrome
• Brain Cancer
• Others

Drug Delivery Across Blood Brain Barrier Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug Delivery Across Blood Brain Barrier Market.

Available Customizations:

Global Drug Delivery Across Blood Brain Barrier market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Drug Delivery Across Blood Brain Barrier Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Trojan Horse Approach, Bispecific Antibody RMT Approach, Increasing the Permeability of BBB, Passive Diffusion, and Others)
  • 5.2.2. By Application (Alzheimer's Disease, Epilepsy, Parkinson's Disease, Multiple Sclerosis, Hunter's Syndrome, Brain Cancer, and Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Drug Delivery Across Blood Brain Barrier Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Drug Delivery Across Blood Brain Barrier Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application

7. Europe Drug Delivery Across Blood Brain Barrier Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
  • 7.3.3. Italy Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
  • 7.3.4. France Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Drug Delivery Across Blood Brain Barrier Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application

8. Asia-Pacific Drug Delivery Across Blood Brain Barrier Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
  • 8.3.2. India Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application

9. South America Drug Delivery Across Blood Brain Barrier Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. Middle East and Africa Drug Delivery Across Blood Brain Barrier Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Drug Delivery Across Blood Brain Barrier Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Ossianix Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Insightec Ltd.
• 14.3. F. Hoffmann-La Roche Ltd
• 14.4. JCR Pharmaceuticals Co., Ltd.
• 14.5. Lauren Sciences LLC
• 14.6. Bioasis Technologies Inc.
• 14.7. Ceres Brain Therapeutics
• 14.8. Nanomerics Ltd.
• 14.9. NEUWAY Pharma GmbH
• 14.10. Genervon Biopharmaceuticals LLC

15. Strategic Recommendations

16. About Us & Disclaimer